By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Drugs in Development Information for AT7519
Email this page to a colleague
What is the development status for investigational drug AT7519?
AT7519 is an investigational drug.
There have been 5 clinical trials for AT7519.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are Astex Pharmaceuticals, NCIC Clinical Trials Group, and Multiple Myeloma Research Consortium.
There are forty-two US patents protecting this investigational drug and three hundred and eighty-one international patents.
Summary for AT7519
| US Patents | 42 |
| International Patents | 381 |
| US Patent Applications | 232 |
| WIPO Patent Applications | 104 |
| Japanese Patent Applications | 45 |
| Clinical Trial Progress | Phase 2 (2012-08-01) |
| Vendors | 61 |
Recent Clinical Trials for AT7519
| Title | Sponsor | Phase |
|---|---|---|
| Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | National Cancer Institute (NCI) | Phase 1 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia | Astex Pharmaceuticals | Phase 2 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia | NCIC Clinical Trials Group | Phase 2 |
Clinical Trial Summary for AT7519
Top disease conditions for AT7519
Top clinical trial sponsors for AT7519
US Patents for AT7519
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AT7519 | Get Started Free | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | Get Started Free |
| AT7519 | Get Started Free | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Get Started Free |
| AT7519 | Get Started Free | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (Basel, CH) | Get Started Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AT7519
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AT7519 | Australia | AU2014348657 | 2033-11-13 | Get Started Free |
| AT7519 | Australia | AU2017245411 | 2033-11-13 | Get Started Free |
| AT7519 | Australia | AU2019246853 | 2033-11-13 | Get Started Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
